-
FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer
Tuesday, February 23, 2021 - 7:17am | 373Read More...The FDA approved expanded use of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi’s SA (NASDAQ: SNY) immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced lung cancer, marking the third approval for Libtayo and second...
-
Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally
Tuesday, February 9, 2021 - 8:23am | 320Read More...Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC). Median...
-
Eli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer
Wednesday, February 3, 2021 - 5:24am | 186Read More...Eli Lilly and Company (NYSE: LLY) and its collaborating partner Innovent Biologics Inc (OTC: IVBXF) has announced that the National Medical Products Administration (NMPA) of China has approved the supplemental marketing application seeking approval for TYVYT (...
-
Mirati Therapeutics Sitravatinib Data, Explained
Friday, September 15, 2017 - 9:42am | 395Read More...Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...
-
Morgan Stanley's Positive Comments On Bristol-Myers Squibb
Monday, June 15, 2015 - 3:30pm | 298Read More...In a report published Monday, Morgan Stanley analyst David Risinger and his team reiterated an Overweight rating on Bristol-Myers Squibb Co (NYSE: BMY) after the National Comprehensive Cancer Network (NCCN) updated its guidelines for the treatment of Non-Small Cell Lung Cancer (NSCLC) to...
